Drug or treatment

Obinutuzumab clinical trials

• 56Clinical trials
• 32Countries

Newest trials

All recruiting trials (56)

• Obinutuzumab beta with low-dose steroids in new-onset ANCA-associated glomerulonephritis

  This study tests whether adding Obinutuzumab beta to a rapid-tapering glucocorticoid plan can help people with new-onset ANCA-associated glomerulonephritis see if they achieve remission.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07746180

• Orelabrutinib with Obinutuzumab and Short-Course Venetoclax in Treatment-Naïve Mantle Cell Lymphoma

  This trial tests whether a combo of orelabrutinib, obinutuzumab, and a short course of venetoclax is safe and effective for adults with newly diagnosed mantle cell lymphoma.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Changzhou, Jiangsu and 1 other locations · NCT07719556

• Obinutuzumab vs steroids for adults with minimal change disease

  This study tests whether obinutuzumab can induce remission in adults with minimal change disease and whether it reduces relapses compared with glucocorticoids.

  Recruiting at 2 sites Phase 2 Medical University Innsbruck · Graz and 5 other locations · NCT07710157

• LUPKYNIS in combination with belimumab, obinutuzumab, or anifrolumab for lupus nephritis

  This trial tests whether adding LUPKYNIS to other biologics (belimumab, obinutuzumab, or anifrolumab) plus a mycophenolic acid analog and a steroid can rapidly improve kidney health in adults with biopsy-proven lupus nephritis.

  Recruiting at 27 sites Phase 4 Aurinia Pharmaceuticals Inc. · La Mesa, California and 26 other locations · NCT07611214

• Zanubrutinib plus obinutuzumab and lenalidomide for first-line follicular lymphoma

  This trial tests whether the combination of zanubrutinib, obinutuzumab, and lenalidomide is safe and effective as a chemotherapy-free first treatment for adults with untreated follicular lymphoma.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT07299149

• Obinutuzumab for non-infectious cryoglobulinemic vasculitis that didn’t respond to rituximab

  This study tests whether obinutuzumab can help adults with active cryoglobulinemic vasculitis who are refractory or intolerant to rituximab.

  Recruiting at 23 sites Phase 2 Assistance Publique - Hôpitaux de Paris · Blois and 24 other locations · NCT07268521

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

• ZGR: zanubrutinib plus obinutuzumab and lenalidomide for newly diagnosed splenic B‑cell lymphoma with prominent nucleoli

  This trial tries the ZGR combination (zanubrutinib, obinutuzumab, and lenalidomide) as first‑line treatment for people with newly diagnosed SBLPN to see if it is effective and well tolerated.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07165769

• Obinutuzumab to reduce PLA2R antibodies in primary membranous nephropathy

  We will try obinutuzumab to see if it quickly lowers anti‑PLA2R antibody levels in adults with high‑risk primary membranous nephropathy who still have heavy proteinuria despite ACEi/ARB treatment.

  Recruiting Phase 2/3 Radboud University Medical Center · Nijmegen · NCT07163611

• Fixed-duration zanubrutinib plus bendamustine and obinutuzumab for newly diagnosed advanced follicular lymphoma

  This tests a six-cycle combination of zanubrutinib, bendamustine, and obinutuzumab for adults with newly diagnosed advanced-stage follicular lymphoma.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07126678

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• Acalabrutinib and Venetoclax for relapsed CLL/SLL after initial BTKi+BCL2i response

  This trial tests a finite-duration combination of acalabrutinib and venetoclax in adults whose CLL or SLL has relapsed after a first-line BTKi+BCL2i therapy and who had at least 2 years of response.

  Recruiting at 16 sites Phase 2 AstraZeneca · Boston, Massachusetts and 46 other locations · NCT07024706

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• Time-limited combination of pirtobrutinib, venetoclax and obinutuzumab for relapsed CLL/SLL

  This trial will test whether a time-limited combination of pirtobrutinib, venetoclax, and obinutuzumab can control relapsed CLL/SLL in adults who have had prior therapy.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06967610

• Comparing sonrotoclax combinations versus venetoclax plus rituximab for relapsed or refractory CLL/SLL

  This trial will test whether sonrotoclax combined with obinutuzumab or with rituximab works better than venetoclax plus rituximab for adults whose CLL/SLL has come back or not responded to prior treatment.

  Recruiting at 181 sites Phase 3 BeOne Medicines · Laguna Hills, California and 194 other locations · NCT06943872

• Obinutuzumab to induce remission in relapsing PR3-ANCA granulomatosis with polyangiitis

  This trial will try obinutuzumab to bring about clinical and blood-marker remission in adults with relapsing PR3-ANCA granulomatosis with polyangiitis.

  Recruiting Phase 2 Assistance Publique - Hôpitaux de Paris · Paris · NCT06940661

• Glofitamab after obinutuzumab pre-treatment for central nervous system lymphoma

  This trial will test if giving glofitamab after a short obinutuzumab pre-treatment is safe and helpful for adults with primary or secondary central nervous system lymphoma.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06922604

• Zanubrutinib, obinutuzumab, and sonrotoclax for newly diagnosed CLL or SLL

  This trial tests whether the three‑drug combination of zanubrutinib, obinutuzumab, and sonrotoclax can produce undetectable measurable residual disease (uMRD) in people with previously untreated CLL or SLL.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06849713

• ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

  This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

  Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

• Combination treatment for marginal zone lymphoma patients

  This study is testing a new combination of two drugs, Linperlisib and obinutuzumab, to see if they can safely help patients with marginal zone lymphoma as their first treatment.

  Recruiting Phase 1/2 The First Hospital of Jilin University · Changchun, Jilin · NCT06592170

• Orelabrutinib and Obinutuzumab for Treating Marginal Zone Lymphoma

  This study is testing a new treatment combining Orelabrutinib and Obinutuzumab for people with previously untreated Marginal Zone Lymphoma to see if it works better and is safer than traditional chemotherapy.

  Recruiting Phase 2 Huai'an First People's Hospital · Huai'an, Jiangsu · NCT06566807

• Comparing two treatment combinations for Hairy Cell Leukemia

  This study is testing whether a new combination of drugs can work better and cause fewer side effects than the standard treatment for patients with Hairy Cell Leukemia who have a specific genetic mutation.

  Recruiting at 8 sites Phase 2 Memorial Sloan Kettering Cancer Center · Boston, Massachusetts and 9 other locations · NCT06561360

• Combining Zanubrutinib and Obinutuzumab for Treating Newly Diagnosed Follicular Lymphoma

  This study is testing a new combination of two medications, Zanubrutinib and Obinutuzumab, to see if they can help people with newly diagnosed follicular lymphoma feel better and stay healthy.

  Recruiting Phase 2 The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT06553352

• Combining zanubrutinib and obinutuzumab for untreated chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study is testing if combining two medications, zanubrutinib and obinutuzumab, can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma achieve better treatment results.

  Recruiting at 19 sites Phase 2 PETHEMA Foundation · Alicante and 18 other locations · NCT06544785

• Combination treatment for marginal zone lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated marginal zone lymphoma get better.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06454968

• Evaluating the risk of tumor lysis syndrome in adults with chronic lymphocytic leukemia receiving venetoclax with obinutuzumab or acalabrutinib

  This study is testing if the combination of venetoclax with either obinutuzumab or acalabrutinib is safe for adults with untreated chronic lymphocytic leukemia.

  Recruiting at 69 sites Phase 3 AbbVie · Tucson, Arizona and 69 other locations · NCT06428019

• Glofitamab plus ibrutinib and obinutuzumab for mantle cell lymphoma

  This trial will see if combining glofitamab with ibrutinib and obinutuzumab is safe and effective for adults with previously untreated, high‑risk or age‑65‑and‑older mantle cell lymphoma.

  Recruiting Phase 1/2 OHSU Knight Cancer Institute · Portland, Oregon · NCT06357676

• Fixed-duration treatment for chronic lymphocytic leukemia with pirtobrutinib and obinutuzumab

  This study is testing a year-long treatment combining two medications, pirtobrutinib and obinutuzumab, to see if it helps people with chronic lymphocytic leukemia feel better.

  Recruiting at 4 sites Phase 2 Dana-Farber Cancer Institute · Scarborough, Maine and 3 other locations · NCT06333262

• Using Obinutuzumab to treat Fibrillary Glomerulonephritis

  This study is testing if the drug Obinutuzumab can help adults with fibrillary glomerulonephritis improve their kidney function and slow down the disease.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT06295770

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Using obinutuzumab to maintain response in patients with central nervous system lymphoma

  This study is testing if a medication called obinutuzumab can help people with central nervous system lymphoma stay in remission longer after their initial treatment.

  Recruiting at 6 sites Phase 2 Providence Health & Services · New York, New York and 6 other locations · NCT06175000

• Treatment for high tumor burden follicular lymphoma using obinutuzumab and CC-99282

  This study is testing if a new combination of obinutuzumab and CC-99282 can help people with high tumor burden follicular lymphoma who haven't been treated before feel better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06108232

• Using Obinutuzumab to treat pediatric immune thrombocytopenia

  This study is testing if Obinutuzumab can help teenagers with immune thrombocytopenia who haven't responded well to other treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06094881

• Combination of drugs for treating relapsed large B-cell lymphoma before and after CAR-T therapy

  This study is testing a combination of three drugs to see if they can help people with relapsed large B-cell lymphoma feel better before and after CAR-T therapy.

  Recruiting at 5 sites Phase 2 University College, London · London and 4 other locations · NCT06071871

• Combination therapy for relapsed or refractory mantle cell lymphoma

  This study is testing a new combination of three drugs to see if it can help people with mantle cell lymphoma that hasn't responded to previous treatments.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06054776

• Combination treatment for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma

  This study is testing a new combination of three medications to see if it can help people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting Phase 1 OHSU Knight Cancer Institute · Portland, Oregon · NCT05943496

• Comparing radiotherapy alone versus with Obinutuzumab for early stage follicular lymphoma

  This study is testing if adding Obinutuzumab to radiation therapy helps people with early-stage follicular lymphoma do better than just radiation alone.

  Recruiting at 43 sites Phase 3 Fondazione Italiana Linfomi - ETS · Sassuolo, Modena (MO) and 48 other locations · NCT05929222

• Observing the effects of obinutuzumab for untreated follicular lymphoma

  This study looks at how well the drug obinutuzumab works and how safe it is for people with untreated follicular lymphoma in real-life settings.

  Recruiting Ruijin Hospital · Shanghai, Shanghai Municipality · NCT05899621

• Combination treatment for newly diagnosed high-risk mantle cell lymphoma

  This study is testing a new combination of treatments for people with newly diagnosed high-risk mantle cell lymphoma to see if it helps them live longer without the disease getting worse.

  Recruiting at 3 sites Phase 1/2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT05861050

• Combining obinutuzumab and lenalidomide for treating relapsed follicular lymphoma

  This study is testing if combining obinutuzumab and lenalidomide can help people in China with relapsed follicular lymphoma feel better and live longer, while keeping their current treatment plans.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05846763

• Combining obinutuzumab and lenalidomide for treating relapsed marginal zone lymphoma

  This study is testing a combination of two medications, obinutuzumab and lenalidomide, to see if they can help people with relapsed marginal zone lymphoma feel better.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tian · NCT05846750

• Combination treatment for newly diagnosed chronic lymphocytic leukemia

  This study is testing a new combination treatment for people with newly diagnosed chronic lymphocytic leukemia to see if it helps them achieve better health outcomes.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05536349

• Acalabrutinib combined with venetoclax or obinutuzumab for treating chronic lymphocytic leukemia

  This study is testing if a new combination of two drugs, acalabrutinib with either venetoclax or obinutuzumab, can help people with chronic lymphocytic leukemia who haven't been treated before by reducing cancer cells in their bone marrow.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT05336812

• Combination treatment for high-risk chronic lymphocytic leukemia

  This study is testing if a new combination of three drugs can help people with high-risk chronic lymphocytic leukemia live longer without their cancer getting worse compared to a combination of two drugs.

  Recruiting at 30 sites Phase 3 German CLL Study Group · Bad Saarow and 29 other locations · NCT05197192

• Evaluating Obinutuzumab for Lupus Nephritis in Adolescents

  This study is testing if a medication called obinutuzumab can help teenagers with lupus nephritis feel better and improve their kidney health.

  Recruiting at 33 sites Phase 2 Hoffmann-La Roche · Loma Linda, California and 43 other locations · NCT05039619

• Fixed-duration treatment for chronic lymphocytic leukemia with ibrutinib and obinutuzumab

  This study is testing a new treatment plan using ibrutinib and obinutuzumab for people with chronic lymphocytic leukemia who haven't been treated before, to see if it can help them reach a point where the disease is undetectable in their bone marrow.

  Recruiting Phase 2 IRCCS San Raffaele · Milan, MI · NCT04908228

• Assessing the effects of venetoclax and obinutuzumab in adults with recurring chronic lymphocytic leukemia

  This study is testing if a combination of two medications, venetoclax and obinutuzumab, can help adults with recurring chronic lymphocytic leukemia feel better after their previous treatments.

  Recruiting at 50 sites Phase 2 AbbVie · La Jolla, California and 57 other locations · NCT04895436

• Combining acalabrutinib and obinutuzumab to treat untreated follicular lymphoma and indolent non-Hodgkin lymphomas

  This study is testing if combining two treatments, acalabrutinib and obinutuzumab, can help people with untreated follicular lymphoma and other slow-growing non-Hodgkin lymphomas feel better and improve their quality of life.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT04883437

• Combination treatment for mantle cell lymphoma

  This study is testing a combination of three drugs to see if they can help people with mantle cell lymphoma that has come back or hasn't been treated yet.

  Recruiting at 3 sites Phase 1/2 Dana-Farber Cancer Institute · Chicago, Illinois and 2 other locations · NCT04855695

• Evaluating the safety and effectiveness of ST-067 in treating various solid tumors

  This study is testing a new treatment called ST-067 to see if it can help people with tough-to-treat solid tumors feel better and improve their health.

  Recruiting at 6 sites Phase 1/2 Simcha IL-18, Inc. · Scottsdale, Arizona and 5 other locations · NCT04787042

• Comparing treatments for lupus nephritis without added oral steroids

  This study is testing whether a treatment for lupus nephritis using obinutuzumab and mycophenolate mofetil without steroids can work just as well as a treatment that includes steroids.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Paris · NCT04702256

• Early treatment for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma

  This study tests if starting treatment early with venetoclax and obinutuzumab can help people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma live longer and feel better compared to waiting until symptoms show up.

  Recruiting at 299 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 632 other locations · NCT04269902

• Combining acalabrutinib, venetoclax, and possibly obinutuzumab for treating high-risk chronic lymphocytic leukemia

  This study is testing a combination of three medications to see if they can help people with high-risk chronic lymphocytic leukemia feel better and improve their treatment results.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04169737

• Acalabrutinib with or without Obinutuzumab for early-stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  This study is testing whether a new drug called acalabrutinib, alone or with another drug called obinutuzumab, can help people with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Mayo Clinic · Scottsdale, Arizona and 2 other locations · NCT03516617

• Combination treatment for relapsed B-cell lymphoma

  This study is testing a new combination of five drugs to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT03223610

• Using obinutuzumab with chemotherapy for relapsed CD20+ Non-Hodgkin Lymphoma in young patients

  This study is testing if a new drug called obinutuzumab, alone or with chemotherapy, can help young patients with relapsed CD20 positive Non-Hodgkin Lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 New York Medical College · Valhalla, New York · NCT02393157

Quick answers

How many clinical trials of Obinutuzumab are recruiting right now?

56, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in United States (32 trials), China (14 trials), France (8 trials), Spain (6 trials), Italy (6 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 37, Phase 1/2: 6, Phase 3: 6, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →